Evidence map›Paper›PMID 42122217›Full record

ArticleCancers2026

A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients.

Shimaa Sherif, Aesha Ali, Khadega Ibrahim, Darawan Rinchai, Mohammed Elanbari, Dhanya Kizhakayil, Mohammed Toufiq, Fazulur R Vempalli, Tommaso Mina, Patrizia Comoli and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Shimaa SherifResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0002-0966-7202
Aesha AliResearch Department, Sidra Medicine, Doha 26999, Qatar.
Khadega IbrahimResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0002-9238-5942
Darawan RinchaiResearch Department, Sidra Medicine, Doha 26999, Qatar.
Mohammed ElanbariResearch Department, Sidra Medicine, Doha 26999, Qatar.
Dhanya KizhakayilResearch Department, Sidra Medicine, Doha 26999, Qatar.
Mohammed ToufiqResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0002-6368-6746
Fazulur R VempalliResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0001-7715-3185
Tommaso MinaPediatric Oncology and Hematology Department and Cell Factory, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy.
Patrizia ComoliPediatric Oncology and Hematology Department and Cell Factory, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy.
Kulsoom GhiasDepartment of Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.ORCID 0000-0002-8709-7428
Zehra FadooDepartment of Oncology, Aga Khan University, Karachi 74800, Pakistan.
Sheanna HerreraResearch Department, Sidra Medicine, Doha 26999, Qatar.
Che-Ann LachicaResearch Department, Sidra Medicine, Doha 26999, Qatar.
Enas D K DawoudResearch Department, Sidra Medicine, Doha 26999, Qatar.
Hani BibawiPathology Department, Sidra Medicine, Doha 26999, Qatar.
Sandra SapiaPathology Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0001-6525-4034
Blessing DasonResearch Department, Sidra Medicine, Doha 26999, Qatar.
Anila EjazPediatric Hematology-Oncology Division, Sidra Medicine, Doha 26999, Qatar.
Mohammed Y S AnasPediatric Hematology-Oncology Division, Sidra Medicine, Doha 26999, Qatar.ORCID 0009-0007-8644-2027
Ayman SalehPediatric Hematology-Oncology Division, Sidra Medicine, Doha 26999, Qatar.
Giusy GentilcoreResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0003-3546-8642
Davide BedognettiResearch Department, Sidra Medicine, Doha 26999, Qatar.
Chiara CugnoResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0002-1664-3030
Sara DeolaResearch Department, Sidra Medicine, Doha 26999, Qatar.ORCID 0000-0002-3178-1271

Funding

Italian Ministry of Health Ricerca Corrente 08069119Qatar National Research Fund NPRP8-2297-3-494
6 · The paper itself

Abstract

The immunological composition of the microenvironment has shown relevance for diagnosis, prognosis, and therapy in solid tumors but remains underexplored in acute leukemias. We investigated the significance of the acute myeloid leukemia (AML) bone marrow microenvironment in predicting chemosensitivity and long-term remission in pediatric patients. We analyzed 32 non-promyelocytic pediatric AML patients at diagnosis using a NanoString PanCancer IO 360 assay, RNA sequencing, and deep-phenotype flow cytometry analyses. The findings were validated using the pediatric TARGET AML dataset. A short signature of three interferon (IFN)-related genes (

Indexed as

AMLbone marrow microenvironmentinterferon-related gene signaturetumor

Identifiers

PMID42122217
PMCPMC13162913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.